At Sonnet BioTherapeutics, our primary mission is to pioneer the next generation of oncology-focused immune therapeutics for patients and clinicians. Leveraging our proprietary FHAB technology platform, Sonnet is exploring novel single and bispecific immunomodulatory cytokine therapeutic candidates.

For more information on our clinical trials, please visit the following pages:

SB101: SON-1010 Dose Escalation in Patients with Advanced Solid Tumors

SB102: Study of SON-1010 (IL12-FHAB) in Healthy Adults

SB211: SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

SB221: Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer